A Potential Link to Recurrent Pregnancy Loss: Monoclonal Anti-PF4 Antibodies’ Role
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared a post on X:
”Monoclonal Anti –Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss.”
Read the full article here.
In a newly published article ”Monoclonal Anti–Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss ” in The New England Journal of Medicine (NEJM) by Natalie R. Bavli et al., the role of monoclonal anti-platelet factor 4 antibodies in cases of recurring misscarriage is discussed.
Emerging evidence suggests that monoclonal anti–platelet factor 4 (PF4) antibodies may play a role in persistent thrombotic thrombocytopenia.
In a recent report, two patients with monoclonal anti-PF4 antibody-mediated thrombosis also experienced chronic intermittent thrombocytopenia and recurrent first-trimester pregnancy losses.
This combination of clinical findings points to a potential association between these antibodies and obstetrical complications, including recurrent pregnancy loss.
Further research in larger cohorts is needed to better understand this possible connection and its implications for maternal health.
More on the latest scientific advancements in the field of thrombosis featured in Hemostasis Today.
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 22, 2025, 10:35Evaluating a Novel Human Fibrinogen Concentrate (BT524) for Congenital Fibrinogen Deficiency
-
Oct 22, 2025, 09:37Jurjen Krommenhoek and Colleagues Propose a Clinical Care Pathway for Major Bleeding Survivors
-
Oct 22, 2025, 09:32Ishac Nazy: Proud Moment For Our Team!
-
Oct 22, 2025, 09:16Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 22, 2025, 10:46Conversation with Ferran Nadeu – Touch Haematology Future Leader 2025
-
Oct 22, 2025, 10:32Lynn Malec - The New Director of the CCBD and Pharmacy at Children's Wisconsin
-
Oct 22, 2025, 09:41Deanna Joseph: Feeling Inspired and Deeply Grateful After Attending the 2025 HTRS SEARCH Workshop
-
Oct 22, 2025, 08:41Maryum Salim Reflects on Her Experience at the HTRS SEARCH Workshop
-
Oct 22, 2025, 08:36Emilya Huseynova to Speak at AABB 2025